Skip to content
2000
Volume 10, Issue 2
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.

Loading

Article metrics loading...

/content/journals/emiddt/10.2174/187153010791213119
2010-06-01
2024-12-24
Loading full text...

Full text loading...

/content/journals/emiddt/10.2174/187153010791213119
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test